Browsing Tag

Nasdaq:ABOS

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

Eli Pacheco Nov 10, 2022 0

CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development…

Health

Acumen’s ACU193, an Anti-Amyloid Beta Oligomer Antibody, Granted FDA Fast Track…

Eli Pacheco Oct 24, 2022 0

CHARLOTTESVILLE, Va. and CARMEL, Ind., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) today announced that ACU193, the first clinical-stage monoclonal…

Health

Acumen presents poster describing method to standardize amyloid beta oligomer assays…

Eli Pacheco Aug 1, 2022 0

CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Scientists at Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) have developed a synthetic model to potentially…

Health

Acumen Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results…

Eli Pacheco Mar 17, 2022 0

CHARLOTTESVILLE, Va. and CARMEL, Ind., March 16, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the…